Managers from AstraZeneca rebuffed another offer to relinquish their autonomy, saying Pfizer’s latest bid for the British drugmaker, a Friday night proposal valued at 69.4 billion pounds ($117 billion), was too low. The rejection of the bid, which Pfizer said was final, left the two drugmakers in a stalemate over a deal that would have created the world’s largest drugmaker.